Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks

In my previous and first article about Pfizer Inc. (NYSE: PFE ), I argued that the stock could be a bargain. In the meantime, the stock increased a little bit, but especially in the last few days, it declined again and is now tradingMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitali ...